21 May 2009
The influence of cyclosporine a and rapamycin on the b cell subpopulations in vitro
P Wierzbicki, M Jastrzębska, D Kłosowska, A Korecka, G Korczak-Kowalska, A GórskiAnn Transplant 2009; 14(1): 69-69 :: ID: 880452
Abstract
Background: Data on the influence of immunosuppressive drugs on the generation and functions of the B cell subpopulations including B-1a, B1b, and conventional B2 are limited. B1 cells are important cell population producing natural antibodies and involved in antibacterial humoral responses. Among them B1a subset expresses the pan-T cell surface glycoprotein CD5. This molecule is known to modulate lymphocyte activation and differentiation processes. Compared to B2 cells, B1a are long-lived, non-circulating, with reduced BCR affinity.
Material/Methods: The aim of this study was to compare the effects of two
commonly used immunosuppressive drugs, i.e. cyclosporine A (a calcineurine inhibitor) and rapamycin (a cell division inhibitor), on the induction of the B cell subpopulations. Mononuclear cells were obtained from the whole peripheral blood of healthy blood donors. PBMCs were cultured for five days in the presence or absence of either drug. Then the percentages of CD19, CD11b, and CD5 positive cells on PWM-activated and non-activated cells were determined using appropriate monoclonal antibodies. Flow cytometry was performed with a FACSCalibur (BD Biosciences) and data were analyzed using Cell Quest software.
Results: Although both investigated drugs decreased the percentages of B-1a and B1b cells, the difference was statistically significant only in the B-1a subpopulation. On the other hand, neither drug affected the percentage of B2 cells.
Conclusions: The present study is preliminary and we intend to pursue this
line of research by evaluating the influence of immunosuppressive drugs on the functions of the major B cell subpopulations, especially their capability to produce antibodies.
Keywords: Immunosuppression
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






